Search research articles
Contact Us
Filters
Showing results (121-130 of 144) with videos related to
Page
of 15
Sort By:
Nature Communications
|
February 7, 2019
Intrinsic valley Hall transport in atomically thin MoS<sub>2</sub>
Zefei Wu, Benjamin T Zhou, Xiangbin Cai, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 20, 2018
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C Quon, Aldrich Ong, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
JAMA Oncology
|
April 14, 2022
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial
Eric Leung, Adam P Gladwish, Melanie Davidson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer
Wee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 24, 2026
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma treated with Stereotactic Ablative Radiotherapy
Aneesh Dhar, Shankar Siva, Vivian S Tan, et al.
European Urology Oncology
|
May 7, 2025
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer
Noelia Sanmamed, Ian Dayes, Charles Catton, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 144) with videos related to
Sort By:
Page
of 15
Nature Communications
|
February 7, 2019
Intrinsic valley Hall transport in atomically thin MoS<sub>2</sub>
Zefei Wu, Benjamin T Zhou, Xiangbin Cai, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 20, 2018
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C Quon, Aldrich Ong, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
JAMA Oncology
|
April 14, 2022
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial
Eric Leung, Adam P Gladwish, Melanie Davidson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer
Wee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial
Wee Loon Ong, Patrick Cheung, Hans Chung, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 24, 2026
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma treated with Stereotactic Ablative Radiotherapy
Aneesh Dhar, Shankar Siva, Vivian S Tan, et al.
European Urology Oncology
|
May 7, 2025
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer
Noelia Sanmamed, Ian Dayes, Charles Catton, et al.
Page
of 15